Treatment of diabetic dyslipidemia

American Journal of Cardiology

Volumn 81, Issue 4 A, 1998, Pages 47B-51B

  Garg, Abhimanyu ^a,b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; ESTROGEN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DYSLIPIDEMIA; ESTROGEN THERAPY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0032567918     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00038-1     Document Type: Conference Paper

References (31)

1. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, eds. Diabetes in America. Bethesda: National Institutes of Health, 1995:429-448.
2. Howard BV. Pathogenesis of diabetic dyslipidemia. Diabetes Rev 1995;3:423-432.
3. Reaven GM. Non-insulin-dependent diabetes mellitus, abnormal lipoprotein metabolism, and atherosclerosis. Metabolism 1987;36(suppl 1):1-8.
4. Brunzell JD, Hazzard WR, Motulsky AG, Bierman EL. Evidence for diabetes mellitus and genetic forms of hypertriglyceridemia as independent entities. Metabolism 1975;24:1115-1121.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
6. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990;13:153-169.
7. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
8. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
9. Pyorala K, Pederson TR, Kjekshus J, Faergeman O, Olsson AG, Thorgiersson G, for the Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary artery disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-620.
10. Garg A, Grundy SM. Diabetic dyslipidemia and its therapy. Diabetes Rev 1997;5:425-433.
11. Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318:81-86.
12. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319:24-33.
13. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 1983;80:4124-4128.
14. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, II: the relationship of reduction in incidence of coronary artery disease to cholesterol lowering. JAMA 1984;251:365-374.
15. Garg A, Grundy SM: Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus: a short-term, double-blind, crossover trial. Ann Intern Med 1994;121:416-422.
16. Saku K, Gartside PS, Hynd BA, Kashyap ML. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest 1985;75:1702-1712.
17. Haubenwallener S, Essenburg AD, Barnett BC, Pape ME, DeMattos RB, Krause BR, Minton LL, Auerbach BJ, Newton RS, Leff T, et al. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J Lipid Res 1995;36:2541-2551.
18. Garg A, Grundy SM. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM. Diabetes 1989;38:364-372.
19. Grundy SM, Mok HYI, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981;22:24-36.
20. Shepherd J, Packard CJ, Patsch JR, Gotto AM Jr, Taunton OD. Effects of nicotinic acid on plasma high-density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 1979;63:858-867.
21. Coronary Drug Project Research Group. Clofibrate and niacin in coronary artery disease. JAMA 1975;231:360-381.
22. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W, for the Coronary Drug Project Research Group. Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255.
23. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990;264:723-726.
24. Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, Taborsky GJ Jr, Porte D Jr. Increased B-cell secretory capacity as mechanism for islet adaption to nicotinic acid-induced insulin resistance. Diabetes 1989;38:562-568.
25. Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med 1994; 121:252-258.
26. Glueck CJ, Lang J, Hamer T, Tracy T. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 1994;123:59-64.
27. Stone NJ. Estrogen-induced pancreatitis: a caveat worth remembering. J Lab Clin Med 1994;123:18-19.
28. Nozaki S, Garg A, Vega GL, Grundy SM. Postheparin lipolytic activity and plasma lipoprotein response to omega-3 polyunsaturated fatty acids in patients with primary hypertriglyceridemia. Am J Clin Nutr 1991;53:638-642.
29. Nestel PJ, Connor WE, Reardon MF, Connor S, Wong S, Boston R. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest 1984;74:82-89.
30. Glauber H, Wallace P, Griver K, Brechtel G. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med 1988;108:663-668.
31. Friday KE, Childs MT, Tsunehara CH, Fujimoto WY, Bierman EL, Ensinck JW. Elevated plasma glucose and lowered triglyceride levels from omega-3 fatty acid supplementation in type II diabetes. Diabetes Care 1989;12:276-281.